Compare TXRH & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXRH | AXSM |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.6B |
| IPO Year | 2004 | 2015 |
| Metric | TXRH | AXSM |
|---|---|---|
| Price | $184.42 | $223.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 17 |
| Target Price | $193.78 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 1.1M | 809.2K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 1.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | $57.24 |
| Revenue Next Year | $9.28 | $55.88 |
| P/E Ratio | $97.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $153.83 | $96.09 |
| 52 Week High | $199.99 | $234.29 |
| Indicator | TXRH | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 71.75 | 74.19 |
| Support Level | $165.79 | $148.87 |
| Resistance Level | $190.52 | $234.29 |
| Average True Range (ATR) | 4.51 | 10.66 |
| MACD | 3.25 | 1.75 |
| Stochastic Oscillator | 98.27 | 80.01 |
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches. Geographically, the majority of the firm's restaurants are in the USA, with a few in foreign countries.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.